SNBL USA appoints vp of business development

Mark Crane takes overall responsibility for marketing, sales and business development

SNBL USA, a provider of preclinical services, has announced the arrival of Mark Crane as vice president of business development.

Crane takes responsibility for the company’s marketing, sales and business development efforts. He joins SNBL USA from Ricerca Biosciences where he was vice president of global sales and marketing.

Crane has held similar positions at Bridge Pharmaceutical (formerly GeneLogic), Quest Pharmaceutical Services, and MDS Pharma Services.

SNBL USA is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), one of the largest CROs in Japan.

You may also like

Research & Development

PPD and SNBL form JV to provide clinical development services in Japan

Will combine PPD's clinical development operations in Japan with SNBL's clinical research division
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Drug Delivery

New cancer drug delivery system boosts absorption of Paclitaxel

Researchers from Osaka Metropolitan University have developed a drug-delivery system that effectively delivers anticancer medication to cancerous tissues, potentially offering a solution for therapeutics that are difficult to absorb
Subscribe now